{"id":"W2053180027","doi":"10.1016/j.urology.2008.08.128","title":"POD-6.12: Progression Free Survival in Patients with Metastatic and Recurrent Renal Cancer Treated with Sorafenib: Single Center Experience","year":2008,"lang":"en","type":"article","venue":"Urology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Sorafenib; Renal cell carcinoma; Oncology; Internal medicine; Single Center; Progression-free survival; Overall survival; Kidney cancer; Population; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000258329,0.0001537714,0.000293254,0.00007765846,0.00004656966,0.000004779887,0.00003981762,0.00003475899,0.0000758215],"category_scores_gemma":[0.00001145944,0.00009154877,0.00001743714,0.0001104767,0.0001699405,0.00004937669,0.0000291972,0.00009223336,0.000001417473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009142416,"about_ca_system_score_gemma":0.00005225374,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002840727,"about_ca_topic_score_gemma":0.001616208,"domain_scores_codex":[0.99904,0.00004784329,0.0001504908,0.0003137848,0.0002024516,0.0002454384],"domain_scores_gemma":[0.9995561,0.00003189271,0.00007137457,0.0001895089,0.00005371173,0.0000974675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003323628,0.001547842,0.9865736,0.00001298413,0.00006991375,0.0002090325,0.0007368517,0.000008469504,0.00002242492,0.000005330171,0.000138055,0.007351803],"study_design_scores_gemma":[0.01472143,0.007559609,0.9751938,0.0001225602,0.0001086078,0.00006978866,0.00003185642,0.00003178313,0.0004276278,0.0000040468,0.001601907,0.0001270076],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980341,0.0005860574,0.00001137374,0.0005974321,0.00005507766,0.0004711368,0.00002500545,0.00002011495,0.0001996597],"genre_scores_gemma":[0.9991927,0.0001271366,0.000171853,0.0001675089,0.000021564,0.0002202863,0.00004732816,0.00001689261,0.00003470745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0113978,"threshold_uncertainty_score":0.373325,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02554722578655104,"score_gpt":0.2795757208078784,"score_spread":0.2540284950213273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}